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ABSTRACT
MicroRNAs (miRNAs) are an abundant class of
20–23-nt long regulators of gene expression.
The study of miRNA function in mice and potential
therapeutic approaches largely depend on modi-
fied oligonucleotides. We recently demonstrated
silencing miRNA function in mice using chemically
modified and cholesterol-conjugated RNAs termed
‘antagomirs’. Here, we further characterize the
properties and function of antagomirs in mice.
We demonstrate that antagomirs harbor optimized
phosphorothioate modifications, require 419-nt
length for highest efficiency and can discriminate
between single nucleotide mismatches of the
targeted miRNA. Degradation of different chemi-
cally protected miRNA/antagomir duplexes in
mouse livers and localization of antagomirs in a
cytosolic compartment that is distinct from proces-
sing (P)-bodies indicates a degradation mechanism
independent of the RNA interference (RNAi) path-
way. Finally, we show that antagomirs, although
incapable of silencing miRNAs in the central
nervous system (CNS) when injected systemically,
efficiently target miRNAs when injected locally into
the mouse cortex. Our data further validate the
effectiveness of antagomirs in vivo and should
facilitate future studies to silence miRNAs for
functional analysis and in clinically relevant
settings.
INTRODUCTION
MiRNAs are an abundant class of non-coding
RNA ranging from 20 to 23nt of length that are
post-transcriptional regulators of gene expression.
MiRNAs have been mainly associated with developmen-
tal processes in metazoa such as Caenorhabditis elegans
or Drosophila melanogaster (1). However, evidence also
suggests a role for miRNAs in a wide range of functions
in mammals, including insulin secretion, heart, skeletal
muscle and brain development (2,3). Furthermore,
miRNAs have been implicated in diseases such as cancer
(4) and hepatitis C (5), which make them attractive
new drug targets. In contrast to the widely used RNAi
technology using small interfering RNA (siRNA)
duplexes, strategies to inhibit miRNAs have been less
well investigated. Reverse-complement 20-O-methyl sugar
modiﬁed RNA is frequently being used to block miRNA
function in cell-based systems (6). The use of miRNA
inhibitors in mice, however, remains challenging.
Recently, two independent approaches to silence
miRNAs in vivo have been reported. Our group demon-
strated silencing of miRNAs in mice based on RNA
analogs termed ‘antagomirs’ (7). Antagomirs are RNA-
like oligonucleotides that harbor various modiﬁcations
for RNAse protection and pharmacologic properties such
as enhanced tissue and cellular uptake. They diﬀer from
normal RNA by complete 20-O-methylation of sugar,
phosphorothioate backbone and a cholesterol-moiety at
30-end. Antagomirs eﬃciently silence miRNAs in most
tissues after three injections at 80mg/kg bodyweight (bw)
on consecutive days. Esau et al. recently demonstrated
a diﬀerent strategy to silence miRNA(miR)-122 in mouse
liver (8). They inhibited miR-122 following a four-week
treatment protocol with two injections per week of
12.5–75mg/kg bw of an antisense oligonucleotide (ASO)
harboring a complete 20-O-methoxyethyl and phos-
phorothioate modiﬁcation.
Ultimately the eﬃcient use of oligonucleotides to
target miRNAs for functional studies and therapeutic
use will be dependent on characterizations based on
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could be developed through a more detailed under-
standing of the mechanisms of miRNA silencing. In this
study, we begin to address these questions using regulation
of endogenous miR-122 targets and ﬂuorophore-tagged
antagomirs.
MATERIALS AND METHODS
Synthesis of antagomirs
The single-stranded RNAs and modiﬁed RNA analogs
(antagomirs) were synthesized as previously described (7).
The oligonucleotides used in this study are listed in
Table 1 and a schematic representation of the chemical
modiﬁcations is shown in Figure 1. Quasar-570 (Q570)
phosphoramidite from Biosearch Technologies was
coupled to the 50-terminal under standard solid-phase
phosphoramidite synthesis conditions to obtain ﬂuoro-
phore-tagged antagomir 122 and mm-antagomir-122.
Extended 15-min coupling of quasar-570 phosphoramidite
was carried out at a concentration of 0.1M in CH3CN
in the presence of 5-(ethylthio)-1H-tetrazole activator
followed by standard capping, oxidation and deprotection
aﬀorded labeled oligonucleotides. The Q570 conjugated
sequences were HPLC puriﬁed on an in-house packed
RPC-Source15 reverse-phase column. The buﬀers were
20mM NaOAc in 10% CH3CN (buﬀer A) and 20mM
NaOAc in 70% CH3CN (buﬀer B). Fractions containing
full-length oligonucleotides were pooled and desalted.
Analytical HPLC, CGE and ES LC-MS established the
integrity of the compounds. For duplex generation,
equimolar amounts of miR-122 and antagomir were
heated in 1 PBS at 958C for 5min and slowly cooled
to room temperature.
Table 1. Antagomirs of mir-122 and mir-16 
S. No Sequence Description
15 0-UGGAGUGUGACAAUGGUGUUUGU-30 Mir-122
25 0-ascsaaacaccauugucacacuscscsas-Chol-30 Antagomir-122 (23nt, 6 P¼S)
35 0-csascaaacaccauugucacacucscsascs-Chol-30 Antagomir-122 (25nt, 6 P¼S)
45 0-csasaacaccauugucacacsuscscs-Chol-30 Antagomir-122 (21nt, 6 P¼S)
55 0-asasacaccauugucacascsuscs-Chol-30 Antagomir-122 (19nt, 6 P¼S)
65 0-asascaccauugucacsascsus-Chol-30 Antagomir-122 (17nt, 6 P¼S)
75 0-acaaacaccauugucacacucca-Chol-30 Antagomir-122 (23nt, no P¼S)
85 0-acaaacaccauugucacacuccas-Chol-30 Antagomir-122, (23nt, 1 P¼S)
95 0-ascsasasascsascscsasususgsuscsascsascsuscscsas-Chol-30 Antagomir-122, (23nt, 23 P¼S)
10 50-ascsacacaacacugucacauuscscsas-Chol-30 mm-antagomir-122 (23nt, 6 P¼S, 4mm)
11 50-ascsaaacaccacugucacauuscscsas-Chol-30 mm-antagomir-122 (23nt, 6 P¼S, 2mm)
12 50-ascsaaacaccauugucacauuscscsas-Chol-30 mm-antagomir-122 (23nt, 6 P¼S, 1mm at nt19)
13 50-cscsaaacaccauugucacacuscscsas-Chol-30 mm-antagomir-122 (23nt, 6 P¼S, 1mm at nt1)
14 50-ascsaaacaccacugucacacuscscsas-Chol-30 mm-antagomir-122 (23nt, 6 P¼S, 1mm at nt11)
15 50-UGGAGUGUGACAauGGUGUUUGU-30 MiR-122 (20-O-Me at 10 and 11)
16 50-UsGsGAGUGUGACAAUGGUGUUUsGsU-30 MiR-122 (2 P¼S at each end)
17 50-Q570s-ascaaacaccauugucacacuscscsas-Chol-30 Antagomir-122 (50-Quasar570)
18 50-Q570s-ascacacaacacugucacauuscscsas-Chol-30 Mm-antagomir-122 (4mm, 50-Quasar570)
19 50-csgsccaauauuuacgugcugscsusas-Chol-30 Antagomir-16
 Lower case letters indicate 20-O-methyl-modiﬁed nucleotides; subscript ‘s’ indicates a phosphorothioate linkage and ‘chol’ represents cholesterol
linked through a hydroxyprolinol linkage.
Figure 1. Chemical modiﬁcations used in this study. Schematic
representation of (A) miR-122, (B) antagomir-122, (C) antagomir-122
all P¼S and (D)5 0-Quasar570 labeled antagomir-122.
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All animals were maintained in a C57Bl/6J background
on a 12-h light–dark cycle in a pathogen-free animal
facility at Rockefeller University. Six-week-old mice
received on three consecutive days tail vein injections of
saline or diﬀerent RNAs in 0.2ml per injection at normal
pressure. Liver tissue was harvested 24h after the last
injection or as otherwise indicated.
For cerebral injections, mice were anaesthetized
and antagomir-16 was injected into the left frontal
cortex ( 800ng). Injections of equal volume PBS into
the contralateral area of the right hemisphere served as
controls. After 72h mice were sacriﬁced, blood was
removed through systemic perfusion of the left ventricle
with PBS and a  0.4cm
3 area surrounding the injection
site excised from the cortex.
Northern blotting analysis
Total RNA was isolated using the Trizol protocol
with ethanol precipitation and northern blot analysis
was performed using formamide-containing PAGE
as previously described (7).
RT-PCR
Extraction of total RNA, synthesis of cDNA, and PCR
were performed as previously described (7). Primer
sequences and annealing temperatures are shown in
supplementary materials.
Sucrose density gradientfractionation of liver homogenates
Mice were perfused with ice-cold PBS through the left
ventricle and  100mg liver tissue excised. Cells were
fractionated on continuous sucrose density gradients from
0.4 to 2M as described earlier (9). Fractions were
separated on 14% PAGE containing 8M urea and 20%
formamide. Concentration of 50-Q570-labeled antagomir
in liver fractions was measured using an fmax spectro-
photometer from Molecular devices.
Immunofluorescence
For immunoﬂuorescence of P-bodies and antagomirs,
1mg of Q570-labeled antagomirs were injected in 0.2ml
and normal pressure on Day 1, followed by injection
of 50mg of a Gfp-GW182-expressing DNA-plasmid
(10; kindly provided by Dr E.K. Chan, Gainesville,
Florida, USA) in 2ml PBS and high pressure on Day 2.
On Day 3 mice were anesthetized and perfused through
the left ventricle with 2% paraformaldehyde. Livers were
incubated overnight at 48C in 4% paraformaldehyde,
followed by 16-h incubation in 30% sucrose/PBS (v/v).
Frozen sections (7mm) were mounted on glass slides
and analyzed using a laser-scanning microscope.
Statistical analysis
Results are given as means. Statistical analysis was
performed with Student’s t-test, and the null hypothesis
was rejected at the 0.05 level.
RESULTS
Phosphorothioatemodificationsandlengthofantagomir-122
The antagomir-122 chemistry includes six phosphorothio-
ate backbone modiﬁcations. Two phosphorothioates are
located at the 50-end and four at the 30-end. To test
whether the number of phosphorothioates is critical
for the ability of antagomir-122 to silence miR-122,
we compared four diﬀerent antagomir-122 molecules
that only diﬀer in the number of phosphorothioate
modiﬁcation (P¼S). Injection of antagomir-122at
3 20mg/kg bw with no P¼S into mice did not inﬂuence
miR-122 levels in the liver (Figure 2A). The addition of a
single P¼S did not alter miR-122 levels either as compared
to the antagomir-122 with six P¼S (Figure 2B).
Intriguingly, complete P¼S modiﬁcation of the antag-
omir-122 did not further increase the eﬀect on miR-122
levels (Figure 2B). These results demonstrate that phos-
phorothioates are important for antagomir-122 function,
however, complete replacement of P¼Ob yP ¼S decreases
its eﬃciency. The result can be explained by the enhanced
stability provided by the terminal P¼S-linked antagomir
and the reduced thermodynamic stability of the fully
modiﬁed P¼S antagomir duplex with targeted miRNA.
We also determined the optimal nucleotide length of
antagomirs for silencing endogenous miR-122 levels
in vivo. Addition of two nucleotides or shortening of
antagomir-122 by two nucleotides did not signiﬁcantly
alter its eﬃciency (Figure 2C). However, silencing of
miR-122 was abolished at 3 20mg/kg bw when the
length of antagomir-122 was reduced to 19nt. Together,
these results further elicit the requirement of optimum
number of phosphorothioate modiﬁcations and minimum
Figure 2. Impact of antagomir phosphorothioate modiﬁcations and
antagomir length on miR-122 levels. Northern blots of total RNA
isolated from livers of mice that were treated with diﬀerent antagomir-
122 chemistries at 3 20mg/kg bw. (A,B) Diﬀerent phosphorothioate
modiﬁcations; (C) diﬀerent lengths. ‘P¼S’ indicates phosphorothioate
modiﬁcation. Each lane represents an individual animal.
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The tendency for improved activity of 25-mer antagomir
can be explained on the basis of improved thermodynamic
binding aﬃnity of the 25 mer, which should also have
higher biostability from exonucleases for the core 23 mer.
Dose-and time-dependency of antagomir-122
To investigate the optimal dose- and time-dependency
of antagomir-122, we analyzed miR-122 levels as well
as mRNA levels of endogenous miR-122 targets.
Northern blots show that optimal reduction of miR-122
levels is achieved at antagomir concentrations between
3 40 and 3 80mg/kg bw (Figure 3A). The eﬀect of
3 40mg/kg on miR-122 levels is stable for at least 8 days
(¼5 days after the last injection) (Figure 3B).
The expression of miR-122 targets correlated with the
reduction of miR-122 levels in northern blots and
showed highest upregulation at antagomir concentrations
between 3 40 and 3 80mg/kg bw (Figure 3A).
All targets analyzed showed stable upregulation for at
least 5 days after the last injection (Figure 3B). Together,
the results demonstrate that robust and lasting upregula-
tion of miR-122 targets is achieved at antagomir
concentrations between 3 40 and 3 80mg/kg bw as
early as 24h after the last injection.
Mismatch discrimination of antagomirs
We tested the impact of diﬀerent mismatch numbers in
the antagomir sequence on miR-122 levels and miR-122
targets. Four mismatches, two mismatches or a single
mismatch at position 19 was suﬃcient to prevent down-
regulation of miR-122 and upregulation of three diﬀerent
miR-122 targets (AldoA, Tmed3 and Hfe2) as measured
by RT-PCR (Figure 4A). However, single nucleotide
mismatches at two diﬀerent positions (nt1 or nt11) did
not prevent downregulation of miR-122 levels or target
regulation (Figure 4B). These data demonstrate that
antagomirs can exhibit high sequence speciﬁcity.
However, discrimination at the single nucleotide level is
position-dependent and has to be tested for each
microRNA sequence that is being targeted.
Regulation ofmiR-122 targetsby stabilized duplexes
of miR-122/antagomir-122
We asked whether antagomir-mediated miRNA silencing
involves degradation of the miRNA by analyzing the
Figure 3. Dose- and time-dependency of miR-122 target regulation by
antagomir-122. Steady-state mRNA levels of miR-122 target genes in
livers of mice treated with the indicated amounts of antagomir-122.
Expression was measured by RT-PCR. Each lane indicates an
individual animal. The glyceraldehyde-3-phosphate dehydrogenase
gene (Gapdh) was used as a loading control. Gapdh-RT denotes a
control without reverse transcription. Gene symbols are shown in
accordance with the International Standardized Nomenclature
(www.informatics.jax.org/mgihome/nomen/gene.shtml). The upper row
shows a northern blot of liver RNA for miR-122. Each lane represents
an individual animal. (A) Dose-dependency. (B) Time-course.
Figure 4. Sequence discrimination of antagomir-122. Steady-state
mRNA levels of miR-122 target genes in livers of mice treated with
the indicated amounts of antagomir-122 or antagomir-122 that
harbored 4, 2 or 1nt mismatches, respectively (A), or 1-nt mismatch
at diﬀerent positions (B). Expression was measured using RT-PCR.
Gapdh was used as a loading control, Gapdh-RT denotes a control
without reverse transcription. Each lane represents an individual
animal.
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duplexes. We synthesized duplexes of antagomir-122
and a synthetic miR-122 that harbored modiﬁcations
to protect against diﬀerent RNAse activities. MiR-122
was either protected at the outside (‘out’) with
a phosphorothioate modiﬁcation to protect against
exonucleases or at two consecutive internal positions
(nt13 and nt14 of miR-122; ‘in’) using 20-O-methyl sugar
modiﬁcation (Figure 5A) to protect against endonuclease
activity. Injection of both types of duplexes led to the
appearance of degradation products of the synthetic
miR-122 (Figure 5B). These degradation products did
not appear when the duplexes were directly analyzed on
the polyacrylamide gels or after they had been subjected to
the RNA isolation protocol (Figure 5B, ‘spiked control’).
Furthermore, the spiked control data demonstrate that the
synthetic miRNA was not lost during the isolation
procedure. These data show that both types of stabilized
miR-122 that were bound to the antagomir-122 had been
degraded. Accordingly, both types of protected duplexes
upregulated three diﬀerent miR-122 targets (Figure 5B).
We conclude that antagomir-mediated-silencing of
miRNAs involves target degradation. However, this
process does not depend on exonuclease activity and
seems to diﬀer from the RNAi pathway.
Cellular localization of antagomirs
To localize antagomirs and miRNA in subcellular
compartments, we used 50-Q570-labeled antagomir-122
or Q570-labeled mm-antagomir-122. Q570-labeling did
not impair antagomir-122 function, although silencing
eﬃciency was slightly decreased (data not shown).
First, we fractionated liver homogenates from mice that
had been treated with Q570-mm-antagomir-122 by
ultracentrifugation on sucrose gradients. Northern blot
analysis of various fractions showed a single peak of tRNA
in fraction 2 (Figure 6A). In contrast, miR-122 and mm-
antagomir-122 localized both to two peaks, fraction 2/3
and fraction 7/8 (Figure 6B). We next investigated whether
co-localization of antagomirs and miRNAs involves the
P-body compartment. To visualize P-bodies in mouse liver
in vivo we used a GFP-expressing construct (GFP-GW182)
that has previously been demonstrated to act as a marker
for the P-body compartment (10). We overexpressed
GFP-GW182 in liver using high-pressure high-
volume tail vein injections and analyzed GFP- and
Q570-ﬂuorescence with laser-scanning microscopy.
Figure 5. Regulation of miR-122 targets by chemically protected
antagomir-122/miR-122-duplexes. (A) Schematic description of the
two diﬀerent duplexes used. (B) Steady-state mRNA levels of
miR-122 target genes in livers of mice treated with the indicated
modiﬁed antagomir-122/miR-122-duplexes. Expression was measured
using RT-PCR. Fold-regulation indicates the ratio of expression levels
of the means of mice treated with antagomir-122/miR-122 duplex
compared to the PBS group. The upper row shows a northern blot of
liver RNA for miR-122. As controls, duplexes were added to 5mg total
kidney RNA and loaded on polyacrylamide gels before (‘input’) or
after the Trizol protocol (‘Trizol’). Each lane represents an individual
animal. Gapdh was used as a loading control, Gapdh-RT denotes
a control without reverse transcription.  P50.05;   P50.01;
   P50.001; Student’s t-test compared to PBS.
Figure 6. Localization of antagomir-122 and miR-122 in hepatocytes.
Liver tissue from mice that were treated with 3 80mg/kg
Q570-labeled mm-antagomir-122 was fractionated on a sucrose
gradient following ultracentrifugation. Localization of Q570-labeled
mm-antagomir-122 was analyzed by spectrophotometry (A), localiza-
tion of t-RNA and miR-122 were analyzed using northern blotting of
total RNA isolated from each fraction (B). For subcellular localiza-
tion of antagomirs and P-bodies in mouse liver, mice were treated
with Q570-labeled antagomir-122 and a DNA-plasmid expressing
a GFP-GW182 hybrid as described in the Materials and Methods
section. P-body and Q570-antagomir localizations were visualized using
laser-scanning microscopy (C).
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the cytosol and distinct from P-bodies (Figure 6C).
There was no overlap between these two compartments.
Together, we conclude that antagomirs and miRNA
interact in a cytoplasmic compartment upstream of
P-bodies.
Intracerebral application ofantagomirs
We previously described that systemic injections of
antagomir-16 into tail veins of mice do not inﬂuence the
steady-state levels of miR-16 in the brain. MiR-16 is
ubiquitously expressed including neurons. We tested
whether antagomir-16 can decrease miRNA levels in the
brain when injected directly into the cortex of anesthetized
mice. PBS injections into the contra lateral side of the
same animal served as controls. A single injection of
 0.8mg of antagomir led to a robust decrease in miR-16
expression at 3 days after the injection (Figure 7).
These results demonstrate that direct application of
antagomirs can eﬃciently target miRNAs in tissues that
cannot be reached through tail vein injections.
DISCUSSION
In this study, we characterized the inhibition of miRNAs
with antagomirs in vivo. A detailed understanding of this
process is needed to investigate miRNA function in mice
and exploit their therapeutic potential. Our study provides
a unique platform since its major read-out is based on
the dose-and time-dependent regulation of several endo-
genous and validated targets of miR-122.
Speciﬁcity of drug-like oligonucleotides is important to
minimize oﬀ-target eﬀects and to discriminate between
related miRNAs that sometimes diﬀer by only a single
nucleotide. Previous studies have demonstrated that
locked nucleic acid (LNA) are sensitive to single mismatch
in in-situ staining protocols of zebraﬁsh embryos (11).
Tissue-culture-based luciferase assays indicated that
20-O-methoxyethyl oligonucleotides might have a similar
speciﬁcity (12). In line with these data we show that
the antagomir chemistry enables discrimination of a
single nucleotide. Intriguingly, this eﬀect depends on the
position of the mismatch within the antagomir sequence.
Nucleotide exchanges at the very 50-end of the antagomir
or in the center did not prevent downregulation of
miR-122 levels in northern blots and upregulation of
miR-122 targets. This observation is in agreement with
the work published by Davis et al., who reported a similar
result in luciferase-based assays (12). Asymmetry of
a single nucleotide mismatch may therefore be more
detrimental for targeting miRNAs than symmetric
changes. These data are important for the design of
antagomirs that target speciﬁc members of miRNA
families or when oﬀ-target eﬀects have to be considered.
The mechanism of oligonucleotide-mediated miRNA
silencing is still unknown. Previous data from our group
and others suggested that this process involves degrada-
tion of the miRNA in vitro (12) and in vivo (7,8). Northern
blots of tissue samples treated with antagomirs fail to
detect fragments of the targeted miRNA. This could be
explained by cellular RNase activity that readily degrades
them. We have previously demonstrated that increasing
the cellular amount of endogenous miRNA by introdu-
cing duplexes of miRNA/antagomir leads to detectable
degradation products (7). In this study, we used this
approach to ask whether antagomir-mediated silencing of
miRNA involves a RNA-induced silencing complex
(RISC)-dependent cleavage mechanism. In the RNAi
pathway, the siRNA duplex of passenger strand and
guide strand is integrated into the RISC complex and
the argonaute-2 (Ago2) protein subsequently cleaves the
passenger strand across from the guide strand’s phosphate
bond between position 10 and 11 (13,14). This cleavage
was inhibited by a single 20-O-methylation of the
passenger strand corresponding to nucleotide 11 of
the guide strand (13). Hypothetically, antagomirs could
cleave miRNAs within RISC with the antagomir acting
as the guide strand. To test this, we injected miRNA/
antagomir-duplexes into mice that harbored a 20-O-methyl
endonuclease protection of the microRNA corresponding
to nucleotide 10 and 11 of the antagomir. However,
endonuclease protection between nucleotides 10 and 11
did not prevent the degradation of the miRNA as
demonstrated by abundant miRNA fragments in northern
analysis, nor did it prevent the upregulation of miR-122
targets. Thus Ago2-mediated cleavage is unlikely to
mediate this process. Similar results were obtained when
the miRNA was protected at the outside positions using
Figure 7. Injection of antagomir-16 into mouse cortex. Northern blots
of miR-16 and miR-124 from total RNA isolated from mouse cerebral
cortex that had been injected with antagomir-16 or PBS into the right
and left cerebral hemispheres, respectively. Each pair of lanes represents
an individual animal.
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does not dependent on exonuclease activity either.
However, the fact that miRNA/antagomir-duplexes
regulate miRNA targets suggests antagomir recycling.
The appearance of miRNA fragments of decreased length
suggests that degradation is involved in this recycling
process. Further elucidation of the mechanism of degra-
dation will be important for optimizing miRNA silencing.
To address the subcellular compartment where interac-
tion of miRNA and antagomir occurs we engineered
ﬂurophore-labeled antagomirs. Flurophore labeling of
siRNA has previously been used to evaluate cellular
uptake of siRNA (15,16). Q570-labeled antagomirs were
cleared from the plasma at a t1/2 of  30min (data not
shown), which is considerably faster than the plasma-
clearance of cholesterol-conjugated siRNA of  90min
(17). A striking overlap of the subcellular localization
proﬁles of antagomirs and miRNAs by sucrose gradient
ultracentrifugation analysis of liver homogenates indicates
that they might share subcellular compartments.
Antagomir localization within hepatocytes was strictly
limited to the cytosol. This could explain why antagomirs
did not inﬂuence steady-state levels of the nuclear
precursors of miRNAs (7). We asked whether antagomirs
could localize to P-bodies, since this compartment has
been linked to the miRNA pathway. P-bodies are enriched
in Ago 2 as well as mRNA that is targeted by miRNAs.
It is, however, still unknown to which degree endogenous
miRNAs localize to P-bodies. In any case, we did not
observe any co-localization of antagomirs and P-bodies
and conclude that the interaction of antagomirs and
miRNAs occurs upstream of this compartment.
In this study, we also extended our previous analysis
of the inﬂuence of diﬀerent chemical modiﬁcations
on antagomirs. Phosphorothioate modiﬁcations provide
protection against RNase activity and their lipophilicity
contributes to enhanced tissue uptake. On the other hand,
phosphorothioates decrease the melting temperature of
RNA duplexes (12) and have been shown to be general
inhibitors of cellular RNAse activity (18). Indeed
our results indicate a critical balance of the number of
phosphorothioates within the antagomir chemistry.
While a signiﬁcant number of phosphorothioates increases
eﬃciency, complete phosphorothioate modiﬁcation
decreased eﬃciency. Our data also demonstrate that
antagomirs require419-nt length for optimal function.
Lastly, we demonstrate that antagomirs can eﬃciently
decrease miR-16 levels in mouse brain when injected
locally. Systemic infusions of antagomir-16 do not change
brain levels of miR-16, most likely because of an inability
to cross the blood-brain barrier (7). Local injections of
small amounts of antagomir-16 eﬃciently reduced expres-
sion of this miR-16 in the cortex. This inhibition was
speciﬁc since the expression of other miRNAs was not
aﬀected and no alteration in miR-16 levels were measured
in the contralateral hemisphere that was injected with
PBS. These results suggest that miRNA-inhibitors could
facilitate the elucidation of miRNA function in the CNS.
Diﬀerent chemical modiﬁcations have been described to
block miRNA function in vitro (6,12) or in vivo (7,8).
However, detailed characterizations of these inhibitors
are either lacking or based on heterologous miRNA target
reporter assays (12). In this study, we used the expression
levels of endogenous miR-122 targets as a read-out.
We show that antagomirs can be used in a time- and dose-
dependent fashion to study miRNA targets. Furthermore,
we characterized antagomirs with regard to speciﬁcity,
functional minimal-length requirements and eﬀectiveness
in the CNS following direct application. Our data support
the conclusion that antagomirs will be powerful tools
for further studies on miRNA function in mice and
possibly non-rodent models and enhance the validation of
miRNA inhibitors as potential therapeutics.
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